

REMARKS

The substitute Sequence Listing enclosed herewith has been voluntarily amended to facilitate its administrative processing, and not for reasons related to patentability.

The amendments to <130>, <140>, <141>, <150>, and <151> in the Sequence Listing reflect USPTO filing information. Where appropriate, lines <223> have been added, to define <221> "unsafe" nucleotide residues as --n is a, c, g or t--. Where appropriate, lines <223> have been added, to define <221> "UNSAFE" amino acid residues as -- Xaa can be any naturally occurring amino acid--.

Thus, the substitute Sequence Listing does not include new matter.

A copy of the substitute Sequence Listing in computer readable form, along with the required Statement under 37 C.F.R. 1.825(a) and 1.825(b), are filed simultaneously herewith.

Please charge any necessary fee to Deposit Account 04-1928 (E. I. du Pont de Nemours and Company).

In view of the foregoing, allowance of the above-referenced application is respectfully requested.

Respectfully submitted,



EMIL M. OROZCO, JR.
AGENT FOR APPLICANTS
Registration No. 50,823
Telephone: 302-695-3121
Facsimile: 302-892-1026

Dated: September 12, 2005

Enclosures: substitute Sequence Listing (paper and CRF)